Southern RNA 🧬’s Post

If you or anyone you know is looking for some lab space to jumpstart your research, please reach out! ABI Lab is the place to be ✨ If you don’t believe me, check out this most recent news letter by MetroWest Daily News!

I am participating LSN Webinar to share my two cents on growing interest of JP startups/biotechs on Go-to-market strategy abroad and what improvement is needed to achieve it.

Laekna Therapeutics receives the US FDA approval for P-III LAE002(Afuresertib) + LAE001 for Clinical trial protocol to treat mCRP #laekna #lae002 #lae001 #afuresertib #clinicaltrials #phase3 #phase2 #prostratecancer #mcrp

Freeline and Swan to Spur new AAV Development... I couldn't resist. Syncona announced they are combining Freeline and Swan Bio to create Spur Therapeutics to advance the most viable components of the latter two companies' pipelines. That pipeline will be headlined by Freeline's Gaucher program (on the cusp of starting Ph3), and Swan's candidate in adrenomyeloneuropathy. Syncona previously took Freeline private to create new optionality for the company. This was after AAV headwinds had battered the stock and other candidates reached approval first in their prior lead therapies (hemophilia). This shows there's still interest in AAV and its proven delivery capability to diverse tissues and cells. But there is continuing culling in the industry's pipeline. Want to take a look at that pipeline? or think about how it impacts your own prioritization? Reach out and we can discuss! #venturecapital #genetherapy #pharma https://lnkd.in/g8-ZKp4C

FIRST fund is thrilled to celebrate that TargED Biopharmaceuticals is dosing the first participant in their Phase 1 clinical trial of TGD001—a groundbreaking thrombolytic treatment. This is not just a milestone for TargED, but also a first for the FIRST Fund: the first portfolio company to enter the clinic. From the early days of supporting TargED’s vision, FIRST Fund has been privileged to witness their transformation from academic research—initially supported by the Hartstichting - Dutch Heart Foundation - into a clinical-stage company. Seeing their innovation now poised to potentially transform the treatment of thrombotic disorders, including acute ischemic stroke (AIS) and iTTP, is both inspiring and rewarding. Congratulations to the TargED team for achieving this milestone and for leading the way as a FIRST Fund portfolio company entering the clinic. We look forward to continuing this journey together! #Innovation #Biotech #Thrombosis #ClinicalTrials #FIRSTFund #TargEDBiopharma Read the details using the following link: https://lnkd.in/e5FXhKEX #lifesciences #biotech #thrombolytic

In the QA department at /Company Red/, the team was baffled - false negatives were turning up in 32% of their products! How were they ever going to instill confidence in their customers if this kept happening? Discover how one wise scientist unraveled the mystery with a game-changing solution from Pinnacle Therapeutics. Dive into the story—who knew Gamma could be the hero? #GammaSterilization #Sterilion #SterilionToTheRescue #GammaIrradiation #FalseNegative #Problems #Solutions #ETO #ETOProblems #Irradiators #GujaratIrradiators

🎙️ Explore the advancements & impact of non-human primate alternatives in shaping tomorrow's medicines in this Sitting Down with Vodcast from Drug Discovery World featuring JAX's Adriano Flora:

A tale of perseverance and strategy at 2seventy bio. In just two years, the biotech has weathered layoffs, pipeline reorganizations, fierce competition, FDA safety warnings, and discontinued clinical trials. Yet, CEO Chip Baird credits transparency and a committed staff for keeping the company afloat. Despite the challenges, 2seventy is now on the path to profitability, with Baird predicting reaching that milestone next year. Stay tuned for potential growth strategies once breakeven is achieved. #biotech #perseverance #strategy #celltherapy #CarT #multiplemyeloma #advancedtherapies #regenerativemedicine #lifescience #lifesciences #biotech #biotechnology bluebird bio #milestones #profitability

Time to mark your calendars (Wed, May 15th, 9 am PDT) and sign up for Unbridled Excellence's 7th expert webinar: "Navigating nonclinical development for CGT products: common challenges & lessons learned!" https://bit.ly/UnBrEx7 Senior Principal and Head of Nonclinical Nathan Manley and Senior Consultant Sean O'Farrell will be sharing wisdom gained from the decade of nonclinical strategy support DHC has amassed to date. As an increasing number of CGT products reach the clinic, it becomes more and more possible to identify common pitfalls and how to overcome them. This webinar explores the current state of nonclinical development for CGT products, focusing on big picture questions, such as selection of suitable model systems, dose determination, and design of GLP tox studies. Nate and Sean will discuss how developers are approaching these challenges for different types of CGT products, highlighting key considerations for both cell- and gene-based therapeutics and in the context of the evolving regulatory landscape. Don't miss it!

Last month, we had the privilege of discussing varied pathways for patient-inspired drug development at #BIO2024. Our CEO, Reenie McCarthy, shared about our long-standing and ongoing focus on patient-directed drug development and spoke alongside I. Sika D. of Travere Therapeutics, Danae' Bartke of HCU Network America, Jessica Tome Garcia, Ph.D. of The Michael J. Fox Foundation for Parkinson's Research, and Stacey Frisk of The Rare Disease Company Coalition. In the eight years since the passage of the 21st Century Cures Act, patient involvement in drug development has exploded. Millions of families affected by serious conditions, particularly in #RareDisease, now have time-tested paths to follow in their pursuit of a life-changing treatment. But patient-focused drug development meetings (PFDDs) are only part of the story. In fact, different paths in drug development have emerged as varied as the challenges that patients themselves face every day. This session explored different roads taken by stakeholders to drive patient input into drug development, inspiring hope for those interested in progress toward novel therapies. #not2rare2care